Washington, D.C.– The National Association of Attorneys General (NAAG) sent a letter on behalf of a bipartisan coalition of 38 state and territory attorneys general which calls on the Food and Drug Administration (FDA) to take decisive action against the unlawful sale and distribution of counterfeit and illegally sold GLP-1 drugs, including Mounjaro, Zepbound, Ozempic, and Wegovy. These medications, which are in high demand for weight loss and diabetes management, have become targets for bad actors seeking to profit from supply shortages and high costs.
The coalition of state and territory attorneys general is calling on the FDA to use its broad jurisdiction and resources to lead the campaign against the dangerous adulteration of GLP-1 medications in the U.S. drug supply. They urge the FDA to exercise its statutory authority through investigations, inspections, and enforcement actions to safeguard consumers.
